Literature DB >> 22757682

Meeting the challenges of haemophilia care and patient support in China and Brazil.

Margareth C Ozelo1, Márcia A P Matta, Renchi Yang.   

Abstract

Projects are underway in many developing countries to try to improve the provision of treatment and access to care for people with haemophilia (PWH), as long-term prophylactic treatment, which improves quality of life for PWH, is still restricted to developed countries. In most developing countries, therapy is limited to on-demand treatment or even no replacement treatment at all. Combined with limited healthcare resources, this lack of treatment can lead to a vicious circle of lack of care, disability, unemployment and lack of access to health insurance for haemophilia patients. In China, the establishment of the Haemophilia Treatment Centre Collaborative Network of China (HTCCNC), in conjunction with the World Federation of Hemophilia, has improved haemophilia care and the identification of PWH. In Brazil, on-demand treatment has improved the health of PWH but does not prevent musculoskeletal (MSK) complications, the major cause of deterioration in quality of life for PWH. The Novo Nordisk Haemophilia Foundation BR2 project was therefore designed to improve quality of life of PWH through improvements in their physical, mental and social wellbeing. This paper will briefly review these projects and describe the current status of haemophilia care in these countries. While there is still a long way to go before optimal care becomes a reality for all PWH in developing countries, significant progress has been made, and knowledge of the impact and outcomes of these projects can inform best practice worldwide.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22757682     DOI: 10.1111/j.1365-2516.2012.02890.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre.

Authors:  Min Xuan; Feng Xue; Rongfeng Fu; Yanhui Yang; Lei Zhang; Mengsu Tian; Renchi Yang
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

2.  [Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors].

Authors:  Shi-Qiu Qiu; Jin-Mu Zhuang; Xuan Zhou; Rui-Xue Yin; Zhu-Qin Liu; Fei Ma; Ying-Jia Li; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-10-20

3.  Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.

Authors:  Renchi Yang; Jing Sun; Yongqiang Zhao; Xuefeng Wang; Depei Wu; Despina Tseneklidou-Stoeter; Junde Wu; Nikki Church
Journal:  Haemophilia       Date:  2019-04-17       Impact factor: 4.287

Review 4.  The existing scenario of haemophilia care in Canada and China - A review.

Authors:  Rohan Pratap; Monali Misra; Varun N; Suman Morampudi; Anand Patil; Jayachandra Reddy
Journal:  Hematol Transfus Cell Ther       Date:  2019-10-27

5.  Analysis of hospitalization of people with hemophilia-12 years of experience in a single center.

Authors:  Cuiyun Qu; Wei Liu; Lingling Chen; Lei Zhang; Feng Xue; Renchi Yang
Journal:  Res Pract Thromb Haemost       Date:  2022-07-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.